Literature DB >> 4472155

Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera.

J Siegel, R Rent, H Gewurz.   

Abstract

Protamine sulfate was found to consume large amounts of C selectively during preincubation with sera of individuals in the "acute phase". Marked depletion of C1, C4, and C2 with minimal, if any, depletion of C3-9, was observed. The consumption was time and temperature dependent, occurring most rapidly and extensively at 37 degrees C, 0.10 M relative salt concentration and pH 7.5-8.0; it required calcium ions. It was mediated by a heat-stable nondialyzable factor which separated with C-reactive protein (CRP) during fractionation and purification, correlated with serum CRP levels, and, like other known reactivities of CRP, was inhibited by phosphoryl choline. Preparations of CRP purified either from serum or ascites resulted in consumption of large amounts of C1, C4, and C2 when preincubated with normal serum and protamine. We conclude that CRP is a potent activator of the C system at the level of C1, and that polycations such as protamine sulfate are substrates of CRP which can bring about this activation. It seems not unlikely that one role of CRP in health and disease involves its ability to interact with the C system.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4472155      PMCID: PMC2139624          DOI: 10.1084/jem.140.3.631

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Clinical and experimental studies on C-reactive protein (acute phase protein).

Authors:  P HEDLUND
Journal:  Acta Med Scand Suppl       Date:  1961

2.  Binding properties and specificity of C-reactive protein.

Authors:  E C Gotschlich; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1967-03       Impact factor: 11.205

Review 3.  The complement system of man. 4.

Authors:  S Ruddy; I Gigli; K F Austen
Journal:  N Engl J Med       Date:  1972-09-28       Impact factor: 91.245

4.  Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis.

Authors:  C M Arroyave; H J Müller-Eberhard
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

5.  Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus.

Authors:  G Stålenheim; O Götze; N R Cooper; J Sjöquist; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1973-08

6.  C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils.

Authors:  P A Ward; J H Hill
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

7.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

8.  A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4.

Authors:  P J Lachmann
Journal:  Immunology       Date:  1966-09       Impact factor: 7.397

9.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  The role of properdin in the alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

View more
  58 in total

1.  Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.

Authors:  G Füst; G A Medgyesi; E Rajnavölgyi; M Csécsi-Nagy; K Czikora; J Gergely
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

2.  Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

3.  Fate of rubella genome ribonucleic acid after immune and nonimmune virolysis in the presence of ribonuclease.

Authors:  A Schluederberg; C Ajello; B Evans
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

4.  Perivascular deposits of serum proteins in cerebral cortex in vascular dementia.

Authors:  I Alafuzoff; R Adolfsson; I Grundke-Iqbal; B Winblad
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

Review 5.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

6.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

7.  C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer.

Authors:  Azubuike I Okemefuna; Lasse Stach; Sudeep Rana; Akim J Ziai Buetas; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

8.  Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system.

Authors:  H Jiang; T F Lint; H Gewurz
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

9.  Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction.

Authors:  I Kushner; M L Broder; D Karp
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

10.  Lymphocytes binding C-reactive protein during acute rheumatic fever.

Authors:  R C Williams; K A Kilpatrick; M Kassaby; Z H Abdin
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.